Analytical Data
-
Gene name
PIK3Cd
- Application
-
Alternative Names
p110D; P110δ; Phosphoinositide-3-Kinase C; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00329
-
Expression Region
Val774~Gln1044
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Phosphoinositide 3-kinase delta (PIK3Cd) is a critical member of the class I phosphoinositide 3-kinase (PI3K) family, which plays a significant role in various cellular processes, including cell growth, proliferation, survival, and metabolism. The importance of PIK3Cd is particularly highlighted in the context of the immune system, where it is predominantly expressed in leukocytes and plays a pivotal role in regulating immune responses and inflammatory processes. Dysregulation of PIK3Cd activity has been implicated in various diseases, including immunodeficiencies, autoimmune disorders, and certain cancers, making it an attractive target for therapeutic intervention. Researchers have been exploring the potential of PIK3Cd reprogramming and the use of specific inhibitors to modulate its activity for improved treatment outcomes. The development of recombinant PIK3Cd proteins has enabled detailed biochemical and biophysical studies, allowing for a deeper understanding of its structure-function relationship and interaction with other signaling molecules. This research not only advances our knowledge of the PI3K signaling pathway but also facilitates the design of novel targeted therapies aimed at diseases linked to aberrant PIK3Cd signaling. As such, the study of recombinant PIK3Cd proteins holds great promise for both basic research and the development of future clinical applications.
